TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
April 04, 2022 07:44 ET
|
TG Therapeutics, Inc.
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing...
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
March 10, 2022 08:15 ET
|
TG Therapeutics, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has set a date of April 22, 2022 for the previously...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
March 04, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighting...
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
March 03, 2022 08:00 ET
|
TG Therapeutics, Inc.
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA)...
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
March 01, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 25, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
February 24, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 15, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials...
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
January 24, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a...
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th...